New pricing directive proposals fail to address real issue, says EFPIA
This article was originally published in Scrip
Executive Summary
Proposals to reform the European directive on pharmaceutical pricing processes are a step in the right direction, but there needs to be a wider debate on international price referencing systems that are costing industry billions of Euros worldwide and preventing differential pricing, EFPIA's director general, Richard Bergstrom, told Scrip.